Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. - Wikidata - wikimedia - TriplyDB

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

http://www.wikidata.org/entity/Q50557485

about

A disease spectrum for ITPA variation: advances in biochemical and clinical research Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.An index to predict ribavirin-induced anemia in asian patients with chronic genotype 1 hepatitis C Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes Role of genetic polymorphisms in hepatitis C virus chronic infection.Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.PharmGKB summary: peginterferon-α pathway.Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy.The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean.ITPA (inosine triphosphate pyrophosphatase): from surveillance of nucleotide pools to human disease and pharmacogenetics Individualization of chronic hepatitis C treatment according to the host characteristics.Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.Telaprevir for the treatment of chronic hepatitis C infection.Hepatocellular carcinoma: towards personalized medicine.Host factors determining the efficacy of hepatitis C treatment.Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.The role of pharmacogenetics in the treatment of chronic hepatitis C infection.Review article: genetic factors that modify the outcome of viral hepatitis.Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels.ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.Efficacy and safety of telaprevir with pegylated interferon α-2a and ribavirin in Japanese patients.Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype.Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b.SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan.Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.Distribution of genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and admixed population.ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.

P2860

Q28069352-3AAE4EB2-425D-4267-88A1-0FA7127D98A0 Q28083100-2ED05120-D115-47D8-A8ED-2AC067902D9B Q28606732-C4FFDA7E-DB99-46EE-A63D-BE91DF84D621 Q33404251-405C851E-C6C1-48E9-876F-C5A46E5B8E19 Q35156156-F267AB56-DAAE-4146-9293-E0F8F38D569E Q35226233-EFD41A68-4531-4D20-B795-7713B2097F2F Q35768047-9629575A-152D-4F4C-B1FD-84823930441B Q35779058-8F35358E-ACD1-474E-AA57-71E6D47F26CC Q35869247-E702D559-7A0E-4EEB-8A40-C3314AA2B764 Q36018931-AF540ED3-B8A0-4B7B-BEB9-C625308E1DAC Q36059685-A2747D68-D74D-45B5-A631-2374C327DBD7 Q36457789-4EB9067A-366B-4C19-BCA1-DC4FE0F1CCBF Q36590755-380F05D6-FCBC-43CE-AE2C-FBB29FC1D754 Q36645372-07E7A75D-AEA9-4FE6-B8C4-0EF3EACB28C3 Q36699265-2436BCA4-5928-4EEC-9921-01E8F239BB8F Q37060571-8174FBB9-42FC-4628-B2CA-2EFAA6748357 Q37098107-B71D4BFA-F57D-4C1D-94E0-2D4691CB7285 Q37308142-74327BD4-FCFB-4174-8CBE-47D4F0B48BD7 Q37654502-FF0E676A-0D11-48D5-B4AF-C02EA28EE7B2 Q37678718-7BDAB5C4-6399-41BA-BEBE-3E9C57C83F44 Q37879701-45065472-0DAB-4448-97BB-34D3D6F864AB Q37960561-7B169003-0524-4BE3-8901-7E4A0063AB29 Q37984653-B49DEB74-2404-4488-90CB-0931FAF3E01E Q38056077-33C5BB86-2989-4B2D-A16B-E2E62F5D1B2A Q38093509-4778D056-AB00-4BE1-B5F6-401638CC4E13 Q38151586-51164F45-641E-4245-9AC9-67E6669295BA Q38198089-943F7E9B-01FF-4B3F-A6FE-0F4F58D81701 Q40155391-F5797BAC-1CC0-41E8-A9AB-C6789A05074C Q40363387-6C38180D-F7B8-4340-A9D1-D8609F52D9C2 Q40385212-D7DC04CD-3F3F-41ED-8D76-5B8C326466BB Q40460374-235823FD-2B8B-4C12-9C07-6B2D08DC80C4 Q40721350-70784E8E-5ED2-4175-9106-7908BD03AC43 Q41236221-F9615022-CF39-4E07-AF06-6D844126BE75 Q41473188-012E73AB-7D66-49FB-A339-D58B2F4CB532 Q41547430-B4382A79-7B73-472D-867C-1F42DA248195 Q41750322-BB29FF8B-403B-4AC6-A7A6-79D5D88E762A Q42202049-482E372F-0F1A-463C-87C9-965C1E12543C Q42212457-05D0EED3-995E-4F44-B3DC-F0FFAEBC2053 Q42217800-64D81040-DBA3-48D8-A628-8EAB2033AAE9 Q42223359-764D406B-41E9-414B-8D62-AA728E44D832

P2860

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

http://www.wikidata.org/entity/Q50557485

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Influence of ITPA polymorphism ...... on, ribavirin, and telaprevir.

@en

Influence of ITPA polymorphism ...... on, ribavirin, and telaprevir.

@nl

type

label

Influence of ITPA polymorphism ...... on, ribavirin, and telaprevir.

@en

Influence of ITPA polymorphism ...... on, ribavirin, and telaprevir.

@nl

prefLabel

Influence of ITPA polymorphism ...... on, ribavirin, and telaprevir.

@en

Influence of ITPA polymorphism ...... on, ribavirin, and telaprevir.

@nl

P1433

Q50557485-350D6C34-02FA-4392-8959-7D9E524E5B5A

P1476

Q50557485-059916B5-6A68-4131-85B1-61E133F4EB0C

P2093

Q50557485-11EB23F0-E91C-48F2-B55F-FDE618F1E941

Q50557485-1B0908F1-D0B6-404D-9D57-68BDF9033F74

Q50557485-320AD6E3-C727-4ED7-9026-A6B88FC9B8A7

Q50557485-359FBAF6-C357-4379-B1FD-3F9A3AAF7ABC

Q50557485-428B38A6-E047-4C29-96D5-791EF9C4F18E

Q50557485-66F0F34B-35E0-4F2E-A926-D2954CD7A64D

Q50557485-75D1900E-6EBB-48C0-A2AB-8E7857F2B9D0

Q50557485-AA2C988B-B880-4DAB-BED4-8A4832015863

Q50557485-B611FDB7-C5C0-4D0E-BF10-7B736296C58A

Q50557485-C49FC235-1161-4FD0-82D7-09985AD8F95E

P2860

Q50557485-037D9652-0D3C-47D3-9FE4-F05E25D81445

Q50557485-080D5888-7047-4553-BE04-FD1020FA993C

Q50557485-09065525-7995-435F-B31C-AC8C2665D487

Q50557485-1A2D3FD6-44D1-4B75-B1C4-AEF1D02600CD

Q50557485-28824416-EE14-4C60-BE26-51FAEE688498

Q50557485-36E2847E-7F8F-4131-AE85-C83D223E0FAC

Q50557485-4EA54FA1-CE87-4850-ACDE-8BF20C345962

Q50557485-4F9A39CA-4EC3-41ED-A604-0337005DC154

Q50557485-524A0ADF-7CB7-4C98-82BF-29823EE5BEEA

Q50557485-631A9B18-8E84-4287-98CE-E99DB0F6F300

P304

Q50557485-F7E79939-5113-404C-A977-C0F06E4F9B01

P31

Q50557485-0F14BADF-3086-4A82-8827-4E6356B4F1D6

P356

Q50557485-0EBDE26F-7F5F-45C4-A849-C49A8CAA9469

P407

Q50557485-31AD522C-0212-47BE-AFA8-01A67A09F053

P433

Q50557485-E654F7EA-0390-40D6-9B7E-A1417C6B1560

P478

Q50557485-D087F760-8159-4CC1-9D41-64735CF79F73

P50

Q50557485-2DD2EF88-E21A-4F1F-85BC-510DBE5E8C89

P577

Q50557485-12B85006-7181-4B80-9BFD-20DAF03FD2F2

P5875

Q50557485-EF833EF9-CD6A-4E45-8FCA-0A011EA469B6

P698

Q50557485-AF3685E6-6617-4638-A0A4-90618F7A822A

P356

P1433

P1476

Influence of ITPA polymorphism ...... ron, ribavirin, and telaprevir

@en

P2093

Fumitaka Suzuki

http://www.w3.org/2001/XMLSchema#string

Hiromitsu Kumada

http://www.w3.org/2001/XMLSchema#string

Hitomi Sezaki

http://www.w3.org/2001/XMLSchema#string

Kazuaki Chayama

http://www.w3.org/2001/XMLSchema#string

Kenji Ikeda

http://www.w3.org/2001/XMLSchema#string

Mariko Kobayashi

http://www.w3.org/2001/XMLSchema#string

Masahiro Kobayashi

http://www.w3.org/2001/XMLSchema#string

Miharu Hirakawa

http://www.w3.org/2001/XMLSchema#string

Naoyuki Kamatani

http://www.w3.org/2001/XMLSchema#string

Norio Akuta

http://www.w3.org/2001/XMLSchema#string

P2860

Global epidemiology of hepatitis C virus infection

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.

DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency.

P304

415-421

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.24058

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49766493

http://www.w3.org/2001/XMLSchema#string

P698

21246582

http://www.w3.org/2001/XMLSchema#string